Gregory L. Verdine

New Capabilities

Harvard chemistry professor and company co-founder

The biggest knock against today's blockbuster weight-loss drugs is that they burn muscle along with fat — up to 40% of the weight a patient loses on semaglutide can be lean tissue like muscle and bone. A new class of therapies now entering clinical trials attacks obesity through entirely different biology, targeting genes and metabolic pathways that strip fat while leaving muscle intact. On March 26, 2026, Wave Life Sciences reported that a single injection of its RNA-silencing drug WVE-007 cut visceral fat by 14.3% over six months while patients actually gained 2.4% lean mass — a profile no existing obesity drug can match.

Updated 3 hours ago